RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

NEXT STORY
Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Cell Therapy
PREV STORY
Adamis Receives FDA Approval for ZIMHI
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ideal Image Announces Appointment of Dr. Deanne Mraz Robinson as Chief Medical Officer

author_avatar
NASDAQ Market News

Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122

Documented potential for drug candidate with characteristics like WP1122 to reverse immune suppression HOUSTON, ...

author_avatar
NASDAQ Market News

Global Point-of-Care Imaging Devices Market: Focus on Product Type, Technology Type, Clinical Utility, Application, End User, 23 Countries’ Data, COVID-19 Impact, and Competitive Landscape – Analysis and Forecast, 2020-2030

author_avatar
NASDAQ Market News